Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...